Lacosamide UCB



This medicine is authorised for use in the European Union.


Lacosamide UCB is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients aged 24 years or older.

Lacosamide UCB can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Lacosamide UCB contains the active substance lacosamide and is the same as Vimpat, which is already authorised in the EU. The company that makes Vimpat has agreed that its scientific data can be used for Lacosamide UCB (‘informed consent’).

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Lacosamide UCB
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Epilepsies, Partial
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
UCB Pharma S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Allée de la Recherche 60
B-1070 Bruxelles

Product information

21/12/2022 Lacosamide UCB - EMEA/H/C/005243 - N/0016

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Assessment history

How useful was this page?

Add your rating
1 rating